Loading...
•
Sep 30, 2024
Intellia Q3 2024 Earnings Report
Reported operational highlights and financial results.
Key Takeaways
Intellia Therapeutics reported progress in advancing its pipeline of CRISPR-based gene editing therapies, including the initiation of the HAELO Phase 3 study and continued strong enrollment in the MAGNITUDE Phase 3 study. The company ended the quarter with $944.7 million in cash, cash equivalents and marketable securities.
Received IND clearance from the U.S. FDA to initiate MAGNITUDE-2 Phase 3 trial of nexiguran ziclumeran (nex-z) in patients with hereditary transthyretin (ATTR) amyloidosis with polyneuropathy; on track to initiate study by year-end
Strong patient enrollment continues in the MAGNITUDE Phase 3 study of nex-z for ATTR amyloidosis with cardiomyopathy, tracking ahead of plans
Actively screening patients in the HAELO Phase 3 study of NTLA-2002 for hereditary angioedema (HAE)
On track to dose the first patient by year-end in the Phase 1/2 study of NTLA-3001, an in vivo gene insertion candidate for the treatment of alpha-1 antitrypsin deficiency (AATD)
Forward Guidance
Intellia expects to dose the first patient in the Phase 1/2 study of NTLA-3001 by year-end.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...